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Summary
 
In this study, we use primary embryonic fibroblasts derived from cyclooxygenase-deficient
transgenic embryos to further investigate the role of the two cyclooxygenases, cyclooxygenase
1 (COX-1) and cyclooxygenase 2 (COX-2), in the process of neoplastic transformation. Cells
with either, neither, or both of the cyclooxygenases were transformed by Ha-
 
ras
 
 and/or SV40.
Our results show that when a cyclooxygenase enzyme is present, the transformed cells have
marked increases in COX-2 and/or COX-1 expression. Nevertheless, each type of cell, defi-
cient in either or both cyclooxygenases, can be readily transformed at almost equal efficiency.
Different nonsteroidal antiinflammatory drugs (NSAIDs) were used to examine their possible
antineoplastic effects on the transformed cells, which have various levels of expression of
COX-1 or COX-2. Our results show that NSAIDs suppress the colony formation in soft agar
in a dosage-dependent manner in the absence of the cyclooxygenase(s). Thymidine incorpora-
tion and apoptosis analyses further demonstrate that the NSAIDs are effective in the cyclooxy-
genase-null cells. Our findings with cyclooxygenase knockout cells confirm recent reports that
some of the antiproliferative and antineoplastic effects of NSAIDs are independent of the inhi-
bition of either COX-1 or COX-2. They also show that transformation is independent of the
status of cyclooxygenase expression, suggesting that the involvement of the cyclooxygenases in
tumorigenesis may occur at later steps.
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T
 
wo isoforms of cyclooxygenase (COX),
 
1
 
 COX-1 and
COX-2, have been identified (1–3). The two isozymes
are regulated differently (1–5), and exhibit distinctive func-
tional differences. COX-1 is expressed constitutively in
many cell types, whereas COX-2 is a primary response
gene whose expression may be induced by trauma, growth
factors, tumor promoters, and a variety of cytokines (for a
review, see reference 6). COX-2 was first discovered as
an oncogene-responsive cyclooxygenase (7), and increased
COX-2 expression has been found in a variety of tumors,
including adenomatous polyps, colorectal cancers, and squa-
mous carcinomas (8, 9). It has been shown that overexpression
of the enzyme in colon cells prolongs the cell life span (10)
and leads to resistance to apoptotic death, which some non-
steroidal antiinflammatory drugs (NSAIDs) that are inhibitors
of cyclooxygenases and prostaglandin (PG) synthesis can
reverse (11). Also, mice containing mutations in both the
adenomatous polyposis coli (APC) gene (APC
 
A716
 
2
 
/
 
1
 
) and
the COX-2 gene (COX-2
 
2
 
/
 
2
 
) developed fewer intestinal
polyps than mice with a functional COX-2 gene (12). A
new selective COX-2 inhibitor, SC-58125, suppressed tu-
mor growth in vivo and induced apoptosis in vitro in cell
lines that express high levels of COX-2, but the drug was
ineffective in HCT-116 cells, which have undetectable
levels of cyclooxygenase expression (13). These studies
place COX-2 in a central position of colon carcinogenesis
and suggest that selective COX-2 inhibition may be a use-
ful approach for chemoprevention or even treatment of the
cancers, particularly those with high levels of COX-2 ex-
pression.
 
1
 
Abbreviations used in this paper:
 
 COX, cyclooxygenase; GAPDH, glyceral-
dehyde 3-phosphate dehydrogenase; NSAID, nonsteroidal antiinflamma-
tory drug; TPA, 12-
 
o
 
-tetradecanoylphorbol 13-acetate. 
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Transformation and NSAID Action on Cyclooxygenase-null Cells
 
Despite the extensive investigation in this area, whether
or not the cyclooxygenases and PGs produced by them are
involved in the malignant transformation per se is unclear.
The approach often used for understanding mechanisms has
been to evaluate the effects of NSAIDs, but this suffers
from the drawback of possible antineoplastic effects of
NSAIDs that may be independent of their ability to inhibit
cyclooxygenases (for a review, see reference 14), especially
at the higher concentrations that are sometimes employed.
In an attempt to provide more definitive information
about mechanisms, we studied malignant transformation in
the cell lines we created from transgenic cyclooxygenase
knockout embryos, which lack COX-1, COX-2, or both
COX-1 and COX-2 (15, 16). We find that transformation
by 
 
ras 
 
leads to large inductions of the cyclooxygenases
when the genes are present. Nevertheless, we also find that
all of these cells can be readily transformed in the absence
of either or both cyclooxygenase enzymes. We applied sev-
eral commonly used NSAIDs to the transformed knockout
cells and found that the inhibitory effects of NSAIDs on
cell growth, transformation, and induction of apoptosis also
occur in the absence of either COX-1 or COX-2.
Taken together, our results confirm recent reports that
some of the antiproliferative and antineoplastic effects of
NSAIDs are independent of the inhibition of either COX-1
or COX-2. They also show that transformation is indepen-
dent of the status of cyclooxygenase expression, suggesting
that the involvement of the cyclooxygenases in tumorigen-
esis may occur at later steps.
 
Materials and Methods
 
Collection of Embryonic Fibroblasts from Cyclooxygenase-deficient
Embryos.
 
COX-1
 
1
 
/
 
2
 
 
 
or COX-2
 
1
 
/
 
2
 
 pregnant heterozygous fe-
male mice (15, 16) were killed by CO
 
2
 
 asphyxiation on day 18 after
fertilization. Each embryo was taken from the uterus, separated,
minced, and trypsinized twice with 0.1% trypsin-EDTA-DMEM
for 15 min. Tissue debris were discarded, and cells were pooled by
brief centrifugation and then suspended in DMEM containing 10%
fetal bovine serum. Cells from each of the embryos were grown in
the same medium at 37
 
8
 
C with 5% CO
 
2
 
. PCR analysis was used to
determine the genotypes of each embryo. Primers used are the fol-
lowing: for COX-1 genotyping, 5
 
9
 
-AGGAGATGGCTGCT-
GAGTTGG-3
 
9
 
 and 5
 
9
 
-AATCTGACTTTCTGAGTTGCC-3
 
9
 
were used to detect the intact COX-1 exon 11; 5
 
9
 
-GCAGC-
CTCTGTTCCACATACAC-3
 
9
 
 and 5
 
9
 
-AATCTGACTTTCT-
GAGTTGCC-3
 
9
 
 were used to detect the targeted disruption of
COX-1 exon 11 containing the neomycin gene. For COX-2 geno-
typing, primers 5
 
9
 
-ACACACTCTATCACTGGCAC-3
 
9
 
 and 5
 
9
 
-
AGATTGTTGTCAGTATCTGCC-3
 
9
 
 were used to detect the
endogenous COX-2 gene (the PCR product extending from exon
8 to exon 10); 5
 
9
 
-ACGCGTCACCTTAATATGCG-3
 
9
 
 and 5
 
9
 
-
AGATTGTTGTCAGTATCTGCC-3
 
9
 
 were used to detect the
targeted disruption of COX-2 exon 8 containing the neomycin
gene. COX-1
 
2
 
/
 
2
 
/COX-2
 
2
 
/
 
2
 
 deficient cell lines were developed by
breeding male COX-1
 
2
 
/
 
2
 
/COX-2
 
1
 
/
 
2
 
 mice and female COX-
1
 
1
 
/
 
2
 
/COX-2
 
1
 
/
 
2
 
 
 
mice; cells from these animals were isolated by an
identical protocol as that described above.
 
Western and Northern Blot Analysis.
 
For Western blot analy-
sis, proteins were collected and dissolved in protein lysis buffers
 
(10 mM Tris, pH 7.6, 1% Triton X-100, 100 mM NaCl, and 2
mM PMSF). 20 
 
m
 
g of protein was loaded and separated by 10%
SDS-PAGE. Proteins were then transferred to polyvinylidene di-
fluoride membranes and blotted with polyclonal antibody specific
to murine COX-1 (provided by Dr. William Smith, Michigan
State University, East Lansing, MI) and mAb specific to COX-2
(Transduction Labs). Membranes were also probed with anti–
 
b
 
-actin antibody (Santa Cruz Biotechnology) to normalize
sample differences between the gel lanes. Immunodetection
was done using the Enhanced Chemiluminescence Western
blotting detection system (ECL kits) purchased from Amer-
sham Pharmacia Biotech. For Northern blot analysis, total
RNAs were extracted from the cell with 4 M guanidium thio-
cyanate homogenization buffer (4 M guanidium thiocyanate,
0.5% sodium laurel sarcosinate, 1% 
 
b
 
-mercaptoethanol in 100
mM Tris-HCl, pH 7.5). 20 
 
m
 
g of the total RNA was loaded
and then electrophoresed on formaldehyde agarose gels. The
separated RNAs were transferred to Duralon UV membrane
and hybridized with COX-1– or COX-2–specific cDNA
probes. These membranes were later probed with glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) to normalize the
RNA loading of each sample.
 
Quantification of PG Production.
 
Primary embryonic fibro-
blast cells were seeded in duplicate in 12-well plates and grown
for 24–48 h in DMEM containing 10% fetal bovine serum. Cells
were treated with 100 ng/ml phorbol ester (12-
 
o
 
-tetrade-
canoylphorbol 13-acetate [TPA]) or vehicle for 10 h. PGE2 ac-
cumulations in the medium were measured using RIA kits pur-
chased from Amersham Pharmacia Biotech. Cyclooxygenase
activities were quantified by adding 30 
 
m
 
M free AA to the cul-
ture and measuring PGE2 production after 15 min had elapsed.
The quantity of cells per well was counted using a hemacytome-
ter. The experiments were conducted using primary cultured
cells from several different cyclooxygenase-deficient embryos,
and similar data were recorded.
 
Transformation Assays.
 
Early passage embryonic fibroblasts
were plated in 100- or 60-mm dishes, and 10–20 
 
m
 
g of plasmids
containing pEJ-
 
ras
 
 and SV40 oncogenes were transfected at a 1:1
ratio into the cells by calcium-phosphate precipitation methods.
The cells were allowed to grow for 2 d after transfection, then
split in a 1:3 ratio into new tissue culture plates and cultured for
an additional 2 wk. Plates were fixed with ethanol and subse-
quently stained with Giemsa dyes; foci formed on the plate were
counted. Growing foci were also picked and allowed to grow to
confluence to measure cyclooxygenase expressions.
 
Drug Studies.
 
Cells expressing various levels of cyclooxygen-
ase were plated at the same density in 0.33% soft agar with differ-
ent NSAIDs: indomethacin (Sigma Chemical Co.), NS-398
(Cayman Chemicals), sulindac (Sigma Chemical Co.), ibuprofen
(Sigma Chemical Co.), and piroxicam (Sigma Chemical Co.).
The drugs were dissolved in DMSO, and identical volumes of
top agar containing various concentrations of drugs were replen-
ished at days 2 and 5. Cells were allowed to grow for 2 wk, and
foci were counted. Duplicate plates were counted for each type
of drug at each different concentration.
 
DNA Synthesis.
 
DNA synthesis was estimated by [
 
3
 
H]thy-
midine incorporation into cellular DNA. Cells in triplicate were
plated in 24-well plates for 24 h and then treated with vehicle or
a different NSAID for 24 h. [
 
3
 
H]Thymidine (1 mCi/ml) was
added and allowed to label the cells for 24 h. The cells were
washed twice with cold DMEM, twice with 10% TCA, and
three times with ethanol. The cells were then lysed in NaOH/
SDS, and radioactivity was counted. 
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DNA Fragmentation Analysis.
 
Postconfluent cells were
treated with each of the NSAIDs for 72 h. NSAID-treated and
vehicle-treated cells were washed with PBS and then lysed in
buffer containing 10 mM Tris-HCl (pH 8.0), 1% SDS, and pro-
teinase K. Lysates were digested for 3 h at 55
 
8
 
C and then ex-
tracted with phenol/chloroform. The genomic DNA was precip-
itated in ethanol and resolved on a 1.5% agarose gel at 60 V for 4 h.
 
Results
 
Cyclooxygenase-deficient Cell Lines Do Not Express Their
Native COX-1 and/or COX-2 mRNA Transcripts.
 
Cells from
each embryo were collected and grown as described in Ma-
terials and Methods, the genotype of each cell line was
identified by PCR, and total RNA was used for Northern
blot analyses. As anticipated (Fig. 1, a and b), wild-type
cells express both TPA-inducible COX-2 and constitutive
COX-1 mRNA, whereas cells from COX-1
 
2
 
/
 
2
 
 or COX-
2
 
2
 
/
 
2
 
 embryos each lack expression of their respective wild-
type COX genes. Cells from COX-1
 
2
 
/
 
2
 
/COX-2
 
2
 
/
 
2
 
 defi-
cient embryos lack expression of both COX-1 and COX-2
transcripts. A small amount of abnormal COX-2 transcript
is detected by Northern blot analysis in COX-2
 
2
 
/
 
2
 
 cells;
however, Western blot analyses and measurements of
PGE2 production confirm the disruption of the cyclooxy-
genase genes.
 
COX-1
 
2
 
/
 
2
 
, COX-2
 
2
 
/
 
2
 
, or COX-1
 
2
 
/
 
2
 
/COX-2
 
2
 
/
 
2
 
 Cells
Demonstrate Deficiencies in PG Production from Each of Their Re-
spective Cyclooxygenases.
 
Reports have shown that COX-1
and COX-2 isozymes exhibit distinctive selectivity over a
different source of arachidonic acid (AA). COX-2 is more
efficient at using mitogen-activated endogenous AA,
whereas COX-1 is more efficient at using exogenously
added AA, or AA released by stimuli such as calcium iono-
phore (17, 18). Therefore, we investigated the production
of PGE2 from these cells by measuring metabolism of ei-
ther exogenous AA or endogenous AA. In the presence of
30 
 
m
 
M of added AA (Fig. 2 a), both COX-1– and COX-
2–deficient cells produced less PGE2 than wild-type cells.
TPA stimulation doubled the production of PGE2 in both
wild-type and COX-2–containing cells. In the absence of
added AA (Fig. 2 b), when 8-h PGE2 accumulation was
measured, stimulation by TPA was found to dramatically
increase PGE2 production in both wild-type and COX-2–
containing (COX-1
 
2
 
/
 
2
 
) cells, but the COX-2
 
2
 
/
 
2 
 
cells pro-
duced almost undetectable levels of PGE2 even with an ac-
tive COX-1 enzyme. TPA-activated AA releases were also
measured by labeling the cells with 
 
3
 
H-AA, and all of the
cells, regardless of the presence of the enzymes, demon-
strated similar induction of AA release in response to TPA
or calcium ionophore (data not shown). Also, as expected,
the COX-1
 
2
 
/
 
2
 
/COX-2
 
2
 
/
 
2
 
 cells do not produce detect-
able PGE2 either in the presence or the absence of AA or
TPA. The failure to detect any PG production in the
Figure 1. Northern blot analysis of cyclooxygenase mRNA levels in
embryo fibroblasts upon TPA stimulation. Wild-type (WT), COX-12/2,
COX-22/2, and COX-12/2/COX-22/2 cells were treated with 100 ng/
ml TPA for 2 h. 20 mg of total RNA was loaded and then separated on
formaldehyde agarose gels. The RNAs were then transferred to Duralon
UV membranes and hybridized with COX-2 (a) or COX-1 (b) specific
cDNA probes. The same membranes were also probed with GAPDH to
examine the DNA loading.
Figure 2. PG production in cyclooxygenase-null cells. (a) Wild-type,
COX-12/2, COX-22/2, and COX-12/2/COX-22/2 cells were treated
with or without 100 ng/ml TPA for 2 h. Media were removed, and 30
mM free AA was added into the culture. PGE2 generated within 15 min
was quantified by RIA kits purchased from Amersham Pharmacia Bio-
tech. (b) The same cells were treated with TPA for 8 h. Media were col-
lected and measured directly by the RIA kit. Cell numbers in each well
were counted in a hemacytometer. 
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Transformation and NSAID Action on Cyclooxygenase-null Cells
 
COX-1
 
2
 
/
 
2
 
/COX-2
 
2
 
/
 
2
 
 cells confirms the inactivation of
both genes. Previous studies by Kirtikara et al. (19) showed
that COX-1 or COX-2 is increased in the null cells to
compensate for the deficiency of PG production. Our data
support this finding by showing that in the COX-1
 
2
 
/
 
2
 
cells, PGE2 production was increased both at the basal and
the stimulated level (Fig. 2 b). However, we failed to de-
tect any increased level of PGE2 production in the COX-
2
 
2
 
/
 
2
 
 cells compared with the wild-type cells.
 
Neoplastic Transformation by EJ-ras Plus SV40 Is Indepen-
dent of Cyclooxygenase Expression. To examine the role of
cyclooxygenases in neoplastic transformation, we con-
ducted transformation assays in primary cultured embry-
onic cells. The oncogene ras was used in this study because
its expression contributes to many malignancies, and several
studies, including our unpublished data, have demonstrated
that transformation by ras induces COX-2 gene expression
(20). The expression of a mutant ras gene usually does not
by itself lead to a transformed phenotype in primary cul-
tured cells; additional mutations in other protooncogenes
such as c-myc, or inactivation of tumor suppressor genes
such as p53, are required to achieve a full malignant trans-
formation (21). Thus, we evaluated the contribution of the
cyclooxygenases to the transforming activity of activated
EJ-ras by adding wild-type SV40 viral gene to complete the
transformation. As shown in Table I, transfection of EJ-ras
alone did not induce any foci formation, and transfection of
SV40 alone induced only a few small foci. These foci from
SV40 transformation failed to grow in the 0.33% soft agar
within 2 wk. In contrast, SV40 plus EJ-ras cooperatively
led to dramatically increased foci formation, and these
transformed cells developed a fully transformed phenotype,
as shown by their loss of contact inhibition and their rapid
growth in soft agar and nude mice. By comparing the wild-
type cells and the cells deficient in either or both of the cy-
clooxygenases, our results demonstrate that cells lacking
either or both of the cyclooxygenases can be readily trans-
formed by SV40 plus ras at almost equal frequencies. Both
cyclooxygenase-null cells and wild-type cyclooxygenase-
containing cells showed similar morphology and growth
behavior in soft agar. This result indicates that cyclooxyge-
nases are not required for transformation per se, nor specif-
ically for the operation of the ras-dependent transformation
pathway.
Expression of the cyclooxygenase isozymes in trans-
formed embryonic fibroblasts was analyzed using Western
blots. As shown in Fig. 3 a, six of the seven transformed
clones showed moderate or marked increases of COX-2
expression, and three of them had increases in the expres-
sion of both enzymes. However, one of the clones showed
unchanged expression of both cyclooxygenases, again sug-
gesting that fibroblasts can be transformed without altering
the cyclooxygenase pathway. Interestingly, we found that
the embryo fibroblasts immortalized only by SV40 ex-
pressed less cyclooxygenase, both COX-1 and COX-2,
than the untransformed cells (Fig. 3, b and c). Further stud-
ies confirmed that the corresponding cyclooxygenase prod-
uct, PGE2, was dramatically reduced in the cells that were
transformed by SV40 alone (data not shown). Isoenzyme
expression was also measured in cells lacking either cy-
clooxygenase (Fig. 3, c and d). In the cells lacking COX-1,
transformation by EJ-ras plus SV40 led to an increased basal
expression of COX-2 (Fig. 3 d, lanes 3–6), and in cells
lacking COX-2, the expression of COX-1 was also mark-
edly increased (Fig. 3 c, lanes 7–10). The results from the
Western blot analyses are consistent with our Northern
blot analyses, further confirming the genotype of each cell
line we used in these studies. Taken together, these experi-
ments illustrate that both cyclooxygenases can be selec-
tively altered by oncogene ras or viral gene SV40; these
actions are oncogene specific and might involve the alter-
ations of signal transduction pathways that lead to the ex-
Table I. Focus Formation of Cyclooxygenase-null Cells Transformed by SV40 and/or EJ-ras
Experiment 1 Experiment 2
Cell type Control SV40 EJ-ras 1 SV40 Control EJ-ras EJ-ras 1 SV40
Wild-type 0 13 150 0 0 50
0 29 107 0 0 22
0 – 166
Cox-22/2 0 13 140 0 0 50
02 0 9 9 0 0 4 9
0 14 144
Cox-21/2 0 14 142
Cox-12/2 0 12 135 0 0 69
0 4 98 0 0 63
Cox-12/2/Cox-22/2 0 3 110 0 0 28
Primary cultures of embryonic fibroblasts were collected as described in Materials and Methods. Cells of each type were transfected with 10–20 mg
of each viral gene by calcium-phosphate precipitation methods. Foci were counted at 14 d after transfection as described.455 Zhang et al.
pression of both cyclooxygenases. However, despite the
changes in cyclooxygenase gene expression, transformation
does occur in the absence of both cyclooxygenases.
NSAIDs Inhibit the Growth of Transformed Cells and also
Induce Apoptosis Regardless of the Presence or Absence of Cy-
clooxygenase Isozymes. Clinical and experimental evidence
strongly suggests that NSAIDs are anticarcinogenic, anti-
proliferative, and antineoplastic. Although some evidence
suggests that the effects of NSAIDs are achieved via their
known inhibitory effects on COX-2, recent data from sev-
eral independent groups demonstrate that some of the ac-
tions may be COX independent. Cells in which either or
both cyclooxygenase genes have been disrupted offer dis-
tinct advantages for evaluation of the antineoplastic activi-
ties of these drugs. For this purpose, we examined the ac-
tions of several NSAIDs on transformed cells with different
deficiencies in the expression of the cyclooxygenase
isozymes. The antineoplastic activities of the drugs were
evaluated by their influence on colony formation in soft
agar, [3H]thymidine incorporation, and by DNA fragmen-
tation analysis. NSAID dosages were varied from 1 to 200
mM, and these dosages are compatible with those used in
several studies where antineoplastic effects were achieved
(11, 22–25). The therapeutic plasma concentration for
NSAID therapy can be achieved with up to 10 mM in-
domethacin, 20 mM sulindac, 20 mM piroxicam, or 300
mM ibuprofen (26). However, it is reported that the local
concentration of NSAIDs in certain organs such as intes-
tines can be built up to an even higher level (27). There-
fore, the dosages we used in these studies include both the
physiological dosages and the higher dosages that might be
achievable in certain organs and tumor tissues in vivo.
We evaluated NSAID actions by seeding the same num-
ber of cells in soft agar containing various concentrations of
different NSAIDs. All of the NSAIDs used (NS-398, sulin-
dac, indomethacin, piroxicam, and ibuprofen) reduced the
size and the number of colonies derived from the cells con-
taining either, neither, or both cyclooxygenase genes in a
dosage-dependent manner, with the inhibition being statis-
tically significant at the higher dosages (Fig. 4). Several cell
clones of each cyclooxygenase-deficient cell line were used
in this study. Quantitative differences in colony formation
were observed in the presence of various NSAIDs, but
these differences were not correlated with the presence or
the absence of cyclooxygenase expression, as seen in Fig. 4.
Thymidine incorporation was used to examine DNA syn-
thesis of the cells in the presence of different NSAID doses.
At the 20 and 100 mM doses of a COX-2–selective
Figure 3. Western blot analysis of cyclooxygenase in wild-type and cyclooxygenase-null cells transformed by SV40 and/or ras. Postconfluent untrans-
formed or transformed MEF cells were treated with or without TPA for 6 h, and the cells were lysed in Triton X-100 as described in Materials and
Methods. Isoenzyme-specific antibodies were used to detect levels of cyclooxygenase expression in wild-type (WT) or cyclooxygenase-null cells. The
same membrane was used to examine protein loadings. (a) Western blot analysis was performed using wild-type cells transformed by SV40 and ras. Col-
onies were selected randomly and expanded for the analysis. (b) Western blot analysis using wild-type cells exhibited decreased expression of both cy-
clooxygenases in SV40-transformed cells and dramatically increased expression of both cyclooxygenases in SV40- and ras-transformed cells. (c) Western
blot analysis demonstrated the lack of the COX-2 protein in COX-22/2 cells. Transformation by SV40 decreased the expression of COX-1, whereas
transformation by SV40 plus ras resulted in increased expression of COX-1 protein. (d) Western blot analysis was performed using COX-12/2 cells and
COX-12/2/COX-22/2 cells. It demonstrated the lack of COX-1 proteins in COX-1 cells and the lack of both COX-1 and COX-2 proteins in the
double knockout cells. Transformation by SV40 plus ras led to increased expression of COX-2 in the COX-12/2 cells.456 Transformation and NSAID Action on Cyclooxygenase-null Cells
NSAID, NS-398, [3H]thymidine incorporation of all four
cell lines examined was reduced by 15–68% regardless of
the presence or absence of the two isozymes (Fig. 5). At
these doses, where PGE2 production was reduced by 95%
in the wild-type cells and the COX-12/2 or COX-22/2
cell lines, further addition of PGE2 up to 10 mM failed to
restore DNA synthesis (data not shown). Finally, we exam-
ined the apoptotic responses of the various deficient cells
upon treatment with the different NSAIDs. At higher
doses (indomethacin 200 mM, sulindac 200 mM, piroxicam
200 mM, NS-398 100 mM, and ibuprofen 1 mM), these
drugs potently induced apoptosis in postconfluent cells at
48–72 h (Fig. 6). The cell death was induced in cells with
neither COX-1 nor COX-2 expression. Based on these re-
sults, we conclude that the antiproliferative and antineo-
plastic actions of NSAIDs in these cells at these concentra-
tions are independent of cyclooxygenase inhibition.
Discussion
The activating mutations of ras occur in z30% of all hu-
man tumors. In squamous carcinomas, these mutations ap-
pear at early or intermediate stages of neoplasia. In colon
cancers, ras gene mutations were found in 50% of adeno-
carcinomas and larger adenomas (28). To initiate studies on
the involvement of the cyclooxygenases in transformation
and malignancy, we developed cells that lack COX-1,
COX-2, or both, and studied ras-induced malignant trans-
formation. We found that transformation by SV40 alone
downregulated the expressions of both cyclooxygenases.
However, addition of the activated ras oncogene induced
malignant transformation accompanied by an increased ex-
pression of either or both cyclooxygenase enzymes. Al-
though most of the clones exhibit increased expression of
either or both cyclooxygenases, some do not express either
Figure 4. Inhibition of colony formation by NSAIDs in soft agar.
Wild-type (WT), COX-12/2, COX-22/2, and COX-12/2/COX-22/2
cells were plated at the same density in 0.33% soft agar and grown for 2
wk as described in Materials and Methods, with the indicated concentra-
tions of the NSAIDs indomethacin (Sigma Chemical Co.), NS-398 (Cay-
man Chemicals), and sulindac (Sigma Chemical Co.). Different cyclooxy-
genase-deficient cell clones were used in this study, and the data
presented are representative. Each value is an average of duplicate plates.
Figure 6. Induction of DNA fragmentation
in cyclooxygenase-null cells (COX-12/2/
COX-22/2) by NSAID treatment. Postconflu-
ent cells were treated with different NSAIDs for
72 h, and genomic DNA was purified and re-
solved on the 1.5% agarose gel as described in
Materials and Methods. Lane 1, 1-kb DNA lad-
der; lane 2, control postconfluent cells with no
treatment of NSAIDs; lanes 3–7, the same cells
treated, respectively, with sulindac (200 mM),
NS-398 (100 mM), ibuprofen (1 mM), piroxi-
cam (200 mM), or indomethacin (200 mM).
Figure 5. Thymidine incorporation of cyclooxygenase-null cells
treated with NS-398, a COX-2–selective NSAID. DNA synthesis was
estimated by [3H]thymidine incorporation into cellular DNA as described
in Materials and Methods. Each value is an average of triplicate wells, and
the t test was used to show statistical differences (*P , 0.05, **P , 0.01).457 Zhang et al.
of the genes at increased levels. This result by itself suggests
that the expression of either cyclooxygenase does not have
a direct implication on mechanisms of transformation. Fur-
thermore, our transformation experiments conducted in
the cyclooxygenase-null cells provide still stronger evidence
that transformation can occur in the absence of either of
the cyclooxygenases, and that cyclooxygenase overexpres-
sion is not necessary to induce neoplastic transformation.
Nevertheless, there is abundant evidence suggesting that
high levels of cyclooxygenase activity do play a critical role
in some malignancies. Recent reports show that forced
overexpression of cyclooxygenase enzymes increases meta-
static potential, invasiveness, and angiogenesis of tumor
cells both in vitro and in vivo (29–31). Moreover, carcino-
genesis is a chronic, sequential, and progressive process that
usually involves accumulation of mutations of protoonco-
genes and tumor suppressor genes in later steps. Mecha-
nisms involving cyclooxygenases in mutagenesis have been
suggested (32, 33). COX-2 overexpression also leads to re-
sistance to apoptosis and increases in the cellular life-span
(10, 11); these phenotypic changes may result in the addi-
tional development of mutations leading to more malignant
behavior. Elevated cyclooxygenase expression is also known
to increase malondialdehyde generation, providing another
mechanism to foster higher cellular mutation rates (34). So
while activation of ras by itself is not usually sufficient for
malignancy, the elevations in cyclooxygenases induced by
the activation of ras could well predispose the cells to muta-
tions in p53 or other genes that participate in the later steps
towards high-grade malignancy. It is also noteworthy that
in addition to COX-2, COX-1 expression is often induced
by the activated ras oncogene, suggesting that both cy-
clooxygenases may serve some overlapping roles in tumori-
genesis. Further studies are required to clarify the functional
differences and relative importance of the two isozymes in
cell malignancy and in the different stages of carcinogenesis.
NSAIDs such as sulindac and indomethacin have been
shown to be beneficial for the prevention and in some cases
for the treatment of certain cancers, although the underly-
ing mechanisms are still unknown. Inhibition of cellular
proliferation and/or induction of apoptosis are reported to
be the mechanisms that cause the regression of tumors in
vivo (35). The antiproliferative and apoptotic effects of
NSAIDs have been documented in a variety of cells and
cell lines, including colon cancer cells, breast cancer cells,
and fibroblasts (22, 23). Considerable recent data suggest
that some of the NSAIDs actions may not be entirely ex-
plained by inhibition of cyclooxygenases. First, some
NSAID-related compounds, which are not cyclooxygenase
inhibitors, can also induce antineoplastic changes in both
the cell cycle and cellular apoptotic responses (36, 37). Sec-
ond, the antineoplastic or anticarcinogenic activity of
NSAIDs may not coincide with the inhibition of PG pro-
duction in some tumor cells and animals (38). Finally,
Hanif et al. (39) found that sulindac and piroxicam inhibit
the growth of and induce apoptosis in HCT-15 cells,
which were shown to produce neither COX-1, COX-2,
nor PGs. Elder et al. (40) also showed that NS-398 induced
apoptosis in S/KS cells, which lack COX-2 protein. In con-
trast, Murphy et al. (41) showed that the growth of the cells
expressing COX-2 was not suppressed by COX-2–selec-
tive inhibitors. In this study, we further illustrate that a se-
lective knockout of cyclooxygenase activity does not change
the ability of NSAIDs to inhibit transformation or to in-
duce apoptosis. These results confirm that inhibition of cy-
clooxygenase is not the only mechanism responsible for the
anticarcinogenic and antineoplastic activity of NSAIDs.
NSAID actions that are independent of cyclooxygenase
have been reviewed by Abramson and Weissmann (42).
New evidence suggests that many of the traditional
NSAIDs have targets other than cyclooxygenases. A recent
report by Herrmann et al. (24) demonstrated that sulindac
sulfide inhibits the ras signaling apparatus, potentially via
an eicosanoid-independent pathway. Lehmann et al. (43)
demonstrate that many NSAIDs are ligands of peroxisome
proliferation–activated receptors (PPARs) a and g. Chan et
al. (25) demonstrated that the elevation of the PG precursor
AA could be involved in the induction of apoptotic re-
sponse by the NSAIDs (i.e., sulindac and indomethacin)
through production of ceramide. However, due to the
higher concentration of NSAIDs used in their study, it is
not clear whether the induction of AA is a result of cy-
clooxygenase enzyme inhibition or direct production of
AA through activation of phospholipases. NSAIDs are a
large group of structurally diverse compounds; therefore,
differences in the actions of individual NSAIDs are also ex-
pected. For example, aspirin inhibits the activation of the
transcription factor NF-kB, whereas indomethacin does
not (44). Recently COX-2–specific inhibitors were dem-
onstrated to have potent antiproliferative effects and to in-
duce apoptosis in cultured cells (20, 45, 46). Whether or
not actions exerted by these drugs are mediated through
inhibition of COX-2 needs additional investigation.
We have also observed in our studies that there are dif-
ferences between cell lines in their sensitivity to NSAIDs
that are independent of cyclooxygenase expression (Fig. 5).
Thus, it seems likely that the differences in the sensitivity of
tumor cell lines to NSAIDs as reported in the literature
may also be independent of cyclooxygenase expression,
particularly when NSAIDs are used at high concentrations.
Finally, the effects of NSAIDs on apoptosis, cell growth,
and DNA synthesis studied here are those often cited to ac-
count for the antitumor activity of this class of compounds,
yet in accord with the results of others, our data show that
NSAID inhibition of the cyclooxygenases does not account
for the antiproliferative and apoptotic actions seen in trans-
formed embryonic fibroblasts. Our results further demon-
strate that although cellular transformation by ras and SV40
usually leads to a dramatic increase in the expression of
COX-1 and COX-2 when present, neither these inductions
nor the presence of either of the enzymes is required for neo-
plastic transformation per se. These results suggest that the in-
volvement of cyclooxygenase expression in neoplastic growth
may occur at steps beyond those involved in transformation.458 Transformation and NSAID Action on Cyclooxygenase-null Cells
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